Global Cervical Cancer Diagnostic Tests Market 2014-2018 29525 Now Available at LifeScienceIndustryResearch.com

Global Cervical Cancer Diagnostic Tests Market 2014-2018

103 pages report Published in Dec 2014

Diagnostics

Publisher: Infiniti Research Limited

Report Description
Table of Content
Related Reports

Cervical cancer diagnostic tests are used to identify the presence of the precancerous or cancerous lesions in the cervix of a woman. These tests include an initial screening using pap smear and HPV testing, and upon positive results, colposcopy and biopsy are further utilized to confirm the diagnosis. After the positive diagnosis, the patient is further subjected to imaging tests that are used to establish the grade of cancer.

TechNavio’s analysts forecast the Global Cervical Cancer Diagnostic Tests market to grow at a CAGR of 10.89 percent over the period 2013-2018.

Covered in this Report

The report covers the present scenario and the growth prospects of the Global Cervical Cancer Diagnostic Tests market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of the following diagnostic test kits and instruments used to diagnose cervical cancer:

Pap Smear Test
HPV Testing
Colposcopy
Biopsy

In addition, the report includes the type of method used to identify cervical cancer:

Molecular method
Cytopathological method
Physical method

Technological types used in cervical cancer identification are also discussed in this report:

ELISA
FISH
NASBA
PCR
Staining & Microscopy
Optical Imaging

TechNavio’s report, the Global Cervical Cancer Diagnostic Tests Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the Global Cervical Cancer Diagnostic Tests market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key Regions

Americas
APAC
EMEA

Key Vendors

Abbott Laboratories
Becton Dickinson
Hologic
Qiagen
Quest Diagnostics
Roche Diagnostics

Other Prominent Vendors

Anthera Pharmaceuticals
Arbor Vita
Autogenomics
Biolight Meditech
BioMerieux
Biovantra
Cancer Genetics
Cervia Diagnostics
Centrel
Cooper Surgical
Cytoimmun
DySIS Medical
Edan
Femasys
Greiner Bio One
Guided Therapeutics
Incell dx
Innogenetics
Kernel Medical
Lutech Industries
Medgyn
Micromedic Technologies
Norchip
Olympus Medical
OncoHealth Corp
Optomic
Optopol Technology
Shenzhen Goldcare Meditech
Sunray
Zilico

Market Driver

Increased Incidence of Smoking
For a full, detailed list, view our report

Market Challenge

Lack of Awareness
For a full, detailed list, view our report

Market Trend

Development of New Diagnostic Platforms
For a full, detailed list, view our report

Key Questions Answered in this Report

What will the market size be in 2018 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings

04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology

05. Introduction

06. Disease Paradigm
06.1 Epidemiology
06.2 Causes of Cervical Cancer
06.3 Diagnosis of Cervical Cancer

07. Market Landscape
07.1 Market Overview
07.2 Market Size and Forecast
07.3 Five Forces Analysis

08. Market Segmentation by Type of Test
08.1 Pap Smear Test
08.1.1 Conventional Pap
08.1.2 Liquid-based cytology
08.2 HPV Testing
08.3 Colposcopy
08.4 Cervical Cancer Biopsy
08.4.1 LEEP
08.4.2 ECC
08.4.3 Cone Biopsy
08.5 Segmentation of Global Cervical Cancer Diagnostic Tests Market by Type of Test
08.6 Global HPV Testing Market
08.6.1 Market Size and Forecast
08.7 Global Colposcopy Market
08.7.1 Market Size and Forecast
08.8 Global Pap Smear Test Market
08.8.1 Market Size and Forecast
08.9 Global Cervical Cancer Biopsy Market
08.9.1 Market Size and Forecast

09. Market Segmentation by Technology
09.1 ELISA
09.2 FISH
09.3 NASBA
09.4 PCR
09.5 Multichromatic Staining and Microscopy
09.6 Optical Imaging

10. Market Segmentation by Method
10.1 Molecular Method
10.2 Cytopathological Method
10.3 Physical Method

11. Geographical Segmentation
11.1 Geographical Segmentation of Global Cervical Cancer Diagnostic Tests Market
11.2 Cervical Cancer Diagnostic Tests Market in Americas
11.2.1 Market Size and Forecast
11.3 Cervical Cancer Diagnostic Tests Market in EMEA Region
11.3.1 Market Size and Forecast
11.4 Cervical Cancer Diagnostic Tests Market in APAC Region
11.4.1 Market Size and Forecast

12. Buying Criteria

13. Market Growth Drivers

14. Drivers and their Impact

15. Market Challenges

16. Impact of Drivers and Challenges

17. Market Trends

18. Trends and their Impact

19. Vendor Landscape
19.1 Competitive Scenario
19.1.1 Key News
19.1.2 Mergers and Acquisitions
19.2 Market Share Analysis 2013
19.3 Other Prominent Vendors

20. Key Vendor Analysis
20.1 Abbott Laboratories
20.1.1 Key Facts
20.1.2 Business Overview
20.1.3 Business Segmentation by Revenue
20.1.4 Business Segmentation by Revenue 2011 and 2012
20.1.5 Geographical Segmentation by Revenue
20.1.6 Business Strategy
20.1.7 Key Information
20.1.8 SWOT Analysis
20.2 Becton, Dickinson and Co.
20.2.1 Key Facts
20.2.2 Business Description
20.2.3 Business Segmentation
20.2.4 Revenue Segmentation by Business
20.2.5 Segmental Revenue Comparison - 2013 and 2012
20.2.6 Revenue Segmentation by Geography
20.2.7 Business Strategy
20.2.8 Key Developments
20.2.9 SWOT Analysis
20.3 Hologic Inc.
20.3.1 Key Facts
20.3.2 Business Overview
20.3.3 Business Segmentation by Revenue 2013
20.3.4 Business Segmentation by Revenue 2012 and 2013
20.3.5 Sales by Geography
20.3.6 Business Strategy
20.3.7 Key Developments
20.3.8 SWOT Analysis
20.4 Qiagen
20.4.1 Key Facts
20.4.2 Business Overview
20.4.3 Product Segmentation by Revenue 2013
20.4.4 Product Segmentation by Revenue 2012 and 2013
20.4.5 Geographical Segmentation by Revenue 2013
20.4.6 Business Strategy
20.4.7 Recent Developments
20.4.8 SWOT Analysis
20.5 Quest Diagnostics
20.5.1 Key Facts
20.5.2 Business Overview
20.5.3 Business Segmentation by Revenue 2013
20.5.4 Business Segmentation by Revenue 2011-2013
20.5.5 Geographical Segmentation by Revenue 2013
20.5.6 Business Strategy
20.5.7 Recent Developments
20.5.8 SWOT Analysis
20.6 Roche Diagnostics
20.6.1 Key Facts
20.6.2 Business Overview
20.6.3 Business Segmentation by Revenue 2013
20.6.4 Geographical Segmentation by Revenue 2013
20.6.5 Business Strategy
20.6.6 Recent Developments

21. Other Reports in this Series

List of Exhibits

Exhibit 1: Market Research Methodology
Exhibit 2: Global Incidence of Cervical Cancer (2013-2018)
Exhibit 3: Global Cervical Cancer Diagnostic Tests Market 2013-2018 (US$ million)
Exhibit 4: Segmentation of Global Cervical Cancer Diagnostic Tests Market by Type of Test
Exhibit 5: Segmentation of Cervical Cancer Diagnostic Test Products by Type of Test
Exhibit 6: Segmentation of Global Cervical Cancer Diagnostic Tests Market by Type of Test 2013-2018 (US$ million)
Exhibit 7: Segmentation of Global Cervical Cancer Diagnostic Tests Market by Type of Test 2013-2018
Exhibit 8: Global HPV Testing Market 2013-2018 (US$ million)
Exhibit 9: Global Colposcopy Market 2013-2018 (US$ million)
Exhibit 10: Global Pap Smear Test Market 2013-2018 (US$ million)
Exhibit 11: Global Cervical Cancer Biopsy Market 2013-2018 (US$ million)
Exhibit 12: Segmentation of Global Cervical Cancer Diagnostic Tests Market by Technology
Exhibit 13: Cervical Cancer Diagnostic Test Products Segmented by Technology
Exhibit 14: Segmentation of Global Cervical Cancer Diagnostic Tests Market by Method
Exhibit 15: List of Tests Segmented Based on Methods used in Cervical Cancer Diagnostic Tests
Exhibit 16: Geographical Segmentation of Global Cervical Cancer Diagnostic Tests Market 2013-2018 (US$ million)
Exhibit 17: Global Cervical Cancer Diagnostic Tests Market by Geographical Segmentation 2013-2018
Exhibit 18: Cervical Cancer Diagnostic Tests Market in Americas 2013-2018 (US$ million)
Exhibit 19: Cervical Cancer Diagnostic Tests Market in EMEA Region 2013-2018 (US$ million)
Exhibit 20: Cervical Cancer Diagnostic Tests Market in APAC Region 2013-2018 (US$ million)
Exhibit 21: Advantages and Limitations of Various Diagnostic Platforms
Exhibit 22: Abbott Laboratories: Business Segmentation by Revenue 2011 and 2012 (US$ million)
Exhibit 23: Abbott Laboratories: Geographical Segmentation by Revenue 2012
Exhibit 24: Product Categorization of Becton, Dickinson and Co.
Exhibit 25: Revenue Segmentation of Becton, Dickinson and Co. 2013
Exhibit 26: Revenue Comparison (US$ million)
Exhibit 27: Revenue Segmentation of Becton, Dickinson and Co. by Geography 2013
Exhibit 28: Revenue Segmentation of Hologic Inc. 2013
Exhibit 29: Revenue Comparison FY2012 and FY2013 (US$ million)
Exhibit 30: Hologic Inc.: Sales by Geography 2013
Exhibit 31: Qiagen: Product Segmentation by Revenue 2013
Exhibit 32: Qiagen: Product Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 33: Qiagen: Geographical Segmentation by Revenue 2013
Exhibit 34: Quest Diagnostics: Business Segmentation by Revenue 2013
Exhibit 35: Quest Diagnostics: Business Segmentation by Revenue 2011-2013 (US$ billion)
Exhibit 36: Quest Diagnostics: Geographical Segmentation by Revenue 2013
Exhibit 37: Roche Diagnostics: Business Segmentation by Revenue 2013
Exhibit 38: Roche Diagnostics: Geographical Segmentation by Revenue 2013

Related Reports

PharmaPoint: Prophylactic Human Papillomavirus Vaccines – Japan Drug Forecast and Market Analysis to 2022The first prophylactic vaccine for immunization against human papillomavirus (HPV) became available in 2006. The global HPV vaccines market is now well established, yet vaccine coverage rates amongst the traditional target population of adolescent girls remain persistently low. Initially HPV vaccines were developed and marketed solely to protect against cervical cancer. In recent years the role of HPV in other cancers has been increasingly recognized which has facilitated a shift […]
2014-2018 Analysis of Emerging Cancer Diagnostic Tests and Strategic Assessments of Leading SuppliersThis 286-page report presents comprehensive marketing and technological assessment, as well as medical rationale and diagnostic prospects, for the major categories of both circulating and cellular tests, such as Biochemical Markers, Oncogenes, Growth Factors, Hormones, Colony Stimulating Factors, Lymphokines, Immunohistochemical Stains and others. The report includes an overview of the clinical significance and market needs for both current and emerging cancer diagnostic tests, as […]
2014-2018 French Molecular Diagnostics Market: Supplier Shares, Country Forecasts, Innovative Technologies, Competitive Strategies–Infectious Diseases, Genetic Diseases, Cancer, Forensic and Paternity TestingThis report presents a comprehensive analysis of the French molecular diagnostics market, including: Major issues pertaining to the French molecular diagnostics laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next ten years. An extensive review of DNA probe and biochip technologies, test formats, detection methodologies, trends in testing automation and amplification […]
2014-2018 Spanish Molecular Diagnostics Market: Supplier Shares, Country Forecasts, Innovative Technologies, Competitive Strategies–Infectious Diseases, Genetic Diseases, Cancer, Forensic and Paternity TestingThis report presents a comprehensive analysis of the Spanish molecular diagnostics market, including: Major issues pertaining to the Spanish molecular diagnostics laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next ten years. An extensive review of DNA probe and biochip technologies, test formats, detection methodologies, trends in testing automation and amplification […]
Hematological Malignancies: Multiple Myeloma (MM) – Early and Robust Diagnosis along with New Treatment Options can have Considerable Impact on Management of the DiseaseWhile targeting unmet needs in the treatment of hematological malignancies/ cancer through innovative drug development strategies have witnessed favorable outcomes, the specific choice of the therapies is dependent on the identification of important genomic alterations in cancerous cells that allow for the tumor’s sub classification. Over the past decade, Proteasome inhibitor and the immunomodulatory drugs have become the cornerstone of treatment for pts with Multiple Myeloma (MM) […]